[Nerve conduction velocity following high-dose vincristine in the treatment of small cell bronchial cancer].
The bicyclic alternating therapeutic regimen employing high-dose vincristine results in very high response rates at acceptable levels of adverse reactions. Neither the motor nor the sensory NCV is significantly influenced by this form of treatment.
Eich
F
F
Abteilung für Pneumologie, Medizinische Klinik und Poliklinik, Universitätskliniken Homburg/Saar.
Emser
W
W
Sybrecht
G W
GW
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011930:Reaction Time / Q000187:drug effects; D009435:Synaptic Transmission / Q000187:drug effects*; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects*
D015251:Epirubicin; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D002945:Cisplatin
Nervenleitgeschwindigkeit (NLG) nach high-dose Vincristin in der Behandlung des kleinzelligen Bronchialkarzinoms (SCLC).